The stock of Textainer Group Holdings Limited (NYSE:TGH) is a huge mover today! About 379,676 shares traded or 46.23% up from the average. Textainer Group Holdings Limited (NYSE:TGH) has risen 68.17% since August 31, 2016 and is uptrending. It has outperformed by 59.57% the S&P500.The move comes after 9 months positive chart setup for the $960.21M company. It was reported on Apr, 7 by Barchart.com. We have $17.38 PT which if reached, will make NYSE:TGH worth $57.61 million more.
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The company has market cap of $580.68 million. The Company’s pipeline includes therapeutic agents designed to target cancer ; prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It has a 53.75 P/E ratio. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation.
Analysts await Textainer Group Holdings Limited (NYSE:TGH) to report earnings on May, 3. They expect $-0.13 EPS, down 218.18% or $0.24 from last year’s $0.11 per share. After $-0.24 actual EPS reported by Textainer Group Holdings Limited for the previous quarter, Wall Street now forecasts -45.83% EPS growth.
Among 6 analysts covering Textainer Group Holdings Limited (NYSE:TGH), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Textainer Group Holdings Limited had 16 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Macquarie Research given on Wednesday, November 4. The stock has “Market Perform” rating by Cowen & Co on Friday, February 12. Macquarie Research downgraded Textainer Group Holdings Limited (NYSE:TGH) on Wednesday, August 5 to “Underperform” rating. The firm has “Outperform” rating given on Monday, January 23 by Cowen & Co. Cowen & Co maintained Textainer Group Holdings Limited (NYSE:TGH) on Wednesday, November 9 with “Market Perform” rating. The company was maintained on Wednesday, August 5 by RBC Capital Markets. The company was maintained on Wednesday, November 4 by Cowen & Co. RBC Capital Markets maintained the shares of TGH in report on Wednesday, November 4 with “Sector Perform” rating. The firm has “Market Perform” rating by Cowen & Co given on Tuesday, August 4. RBC Capital Markets maintained the stock with “Sector Perform” rating in Friday, February 12 report.
Textainer Group Holdings Limited is a holding company. The company has market cap of $960.21 million. The Firm is involved in the purchase, ownership, management, leasing and disposal of a fleet of intermodal containers. It currently has negative earnings. The Firm operates in three divisions: Container Ownership, which owned containers accounting for approximately 80% of the Company’s fleet; Container Management, which managed containers on behalf of approximately 10 affiliated and unaffiliated container investors, providing acquisition, management and disposal services, and total managed containers accounted for approximately 20% of its fleet, and Container Resale, which sells containers from its fleet when they reach the end of their useful lives in marine service, and also purchases and leases or resells containers from shipping line customers, container traders and other sellers of containers.
About 561,053 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 35.83% since August 31, 2016 and is uptrending. It has outperformed by 27.24% the S&P500.
Ratings analysis reveals 100% of Progenics Pharm’s analysts are positive. Out of 4 Wall Street analysts rating Progenics Pharm, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $9 while the high is $14. The stock’s average target of $12.33 is 47.31% above today’s ($8.37) share price. PGNX was included in 6 notes of analysts from August 6, 2015. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Strong Buy” rating by Needham on Monday, February 6. Brean Capital maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) rating on Thursday, August 6. Brean Capital has “Buy” rating and $14 target. Aegis Capital initiated the stock with “Buy” rating in Thursday, October 27 report. Jefferies upgraded it to “Buy” rating and $9 target in Friday, October 23 report. Needham maintained it with “Buy” rating and $11 target in Friday, August 7 report. The firm earned “Buy” rating on Friday, August 7 by Zacks.
Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on May, 4. They expect $-0.21 earnings per share, down 16.67% or $0.03 from last year’s $-0.18 per share. After $-0.10 actual earnings per share reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 110.00% negative EPS growth.
Broadfin Capital Llc holds 8.59% of its portfolio in Progenics Pharmaceuticals, Inc. for 8.95 million shares. Phocas Financial Corp. owns 1.59 million shares or 0.91% of their US portfolio. Moreover, Park West Asset Management Llc has 0.82% invested in the company for 1.23 million shares. The California-based Rice Hall James & Associates Llc has invested 0.48% in the stock. Pinnacle Associates Ltd, a New York-based fund reported 2.66 million shares.
